Nasdaq · CIK 0001720580
ACET Adicet Bio, Inc.
Insider trading from SEC Form 4. Last filing Jun 13, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Adicet Bio, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 20 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 11, 2025 | Katie Peng director | AGrant or award Common Stock | +5,900 | $0.00 | $0 | 11,800 | Jun 13, 2025 |
| Jun 11, 2025 | Steve Dubin director | AGrant or award Common Stock | +5,900 | $0.00 | $0 | 22,700 | Jun 13, 2025 |
| Jun 11, 2025 | Jeffrey Chodakewitz director | AGrant or award Common Stock | +5,900 | $0.00 | $0 | 17,700 | Jun 13, 2025 |
| Jun 11, 2025 | Lloyd Klickstein director | AGrant or award Common Stock | +5,900 | $0.00 | $0 | 108,566 | Jun 13, 2025 |
| Jun 11, 2025 | Andrew Sinclair director | AGrant or award Common Stock | +5,900 | $0.00 | $0 | 17,700 | Jun 13, 2025 |
| Jun 11, 2025 | Andrew Sinclair director | AGrant or award Stock Option (Right to Buy)derivative | +26,400 | $0.00 | $0 | 26,400 | Jun 13, 2025 |
| Jun 11, 2025 | Katie Peng director | AGrant or award Stock Option (Right to Buy)derivative | +26,400 | $0.00 | $0 | 26,400 | Jun 13, 2025 |
| Jun 11, 2025 | Steve Dubin director | AGrant or award Stock Option (Right to Buy)derivative | +26,400 | $0.00 | $0 | 26,400 | Jun 13, 2025 |
| Jun 11, 2025 | Jeffrey Chodakewitz director | AGrant or award Stock Option (Right to Buy)derivative | +26,400 | $0.00 | $0 | 26,400 | Jun 13, 2025 |
| Jun 11, 2025 | Lloyd Klickstein director | AGrant or award Stock Option (Right to Buy)derivative | +26,400 | $0.00 | $0 | 26,400 | Jun 13, 2025 |
| Apr 17, 2025 | Michael Grissinger director | AGrant or award Stock Option (Right to Buy)derivative | +70,200 | $0.00 | $0 | 70,200 | Apr 21, 2025 |
| Jan 31, 2025 | Brian Nicholas Harvey Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +324,040 | $0.00 | $0 | 324,040 | Feb 4, 2025 |
| Jan 31, 2025 | Julia D. Maltzman Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +750,000 | $0.00 | $0 | 750,000 | Feb 4, 2025 |
| Jan 31, 2025 | Don Healey Chief Technology Officer | AGrant or award Stock Option (Right to Buy)derivative | +275,000 | $0.00 | $0 | 275,000 | Feb 4, 2025 |
| Jan 31, 2025 | Chen Schor President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +763,829 | $0.00 | $0 | 763,829 | Feb 4, 2025 |
| Jan 31, 2025 | Blake Aftab Chief Scientific Officer | AGrant or award Stock Option (Right to Buy)derivative | +275,000 | $0.00 | $0 | 275,000 | Feb 4, 2025 |
| Jan 24, 2025 | Brian Nicholas Harvey Chief Financial Officer | FTax withholding Common Stock | -8,752 | $0.92 | $8,068 | 91,048 | Jan 28, 2025 |
| Jan 24, 2025 | Blake Aftab Chief Scientific Officer | FTax withholding Common Stock | -6,270 | $0.92 | $5,780 | 56,241 | Jan 28, 2025 |
| Jan 24, 2025 | Don Healey Chief Technology Officer | FTax withholding Common Stock | -8,560 | $0.92 | $7,891 | 63,769 | Jan 28, 2025 |
| Jan 24, 2025 | Chen Schor President & CEO | FTax withholding Common Stock | -28,101 | $0.92 | $26k | 137,201 | Jan 28, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Blake AftabChief Scientific Officer
- Jeffrey Chodakewitzdirector
- Steve Dubindirector
- Michael Grissingerdirector
- Brian Nicholas HarveyChief Financial Officer
- Don HealeyChief Technology Officer
- Lloyd Klicksteindirector
- Julia D. MaltzmanChief Medical Officer
- Katie Pengdirector
- Chen SchorPresident & CEO
- Andrew Sinclairdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.